Manzo Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNZO research report →
Price Chart
About the company
Manzo Pharmaceuticals, Inc. is a specialized drug company that focuses on the discovery, creation, and evaluation of both proprietary and generic medical treatments and therapies. The company is actively developing Lacto-Freedom, a patented probiotic designed to help individuals with lactose intolerance digest dairy-containing foods more easily.
- CEO
- Kenneth Manzo
- IPO
- 1998
- Employees
- 12
- HQ
- Milford, PA, US
Get TickerSpark's AI analysis on MNZO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.60K
- P/E
- -0.98
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.28
- EV/EBITDA
- 0.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -763.99%
- ROIC
- -27.11%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-52,154
- Net Income
- $-50,851+0.0%
- EPS
- $0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.54
- RSI (14)
- 5
- Avg Volume
- 141.36K
No earnings-call transcripts are available for MNZO yet.
- Free Float
- 34.3%
- Shares Outstanding
- 1.16B
- Float Shares
- 397.78M
Our MNZO coverage
Recent articles, reports, and earnings notes.
No research on MNZO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MNZO report →